Literature DB >> 30320093

Dose Distributions and Treatment Margins in Ocular Brachytherapy with 106Ru Eye Plaques.

Erik Stöckel1, Marion Eichmann1, Dirk Flühs2, Holger Sommer1, Eva Biewald3, Norbert Bornfeld3, Bernhard Spaan1, Wolfgang Sauerwein2.   

Abstract

Brachytherapy with 106Ru eye plaques is the most common treatment modality for small to medium-sized uveal melanomas in Europe. So far, no standardized or widely accepted dose prescription protocol for the irradiation of intraocular tumors with 106Ru eye plaques has been defined. For 125I plaques, the minimum dose required for tumor control should be at least 85 Gy. Concerning 106Ru plaques, the dose prescriptions at the University Hospital of Essen foresees minimum doses of 700 Gy to the tumor base and 130 Gy to the tumor apex. These dose prescriptions are expected to ensure sufficient treatment margins. We apply these dose prescriptions to different eye plaque types and tumor sizes and discuss the resulting treatment margins. These investigations are based on Monte Carlo simulations of dose distributions of 3 different eye plaque types. The treatment margin in apical direction has an expansion of at least 0.8 mm for all investigated eye plaques. For symmetrically formed eye plaques, the treatment margin at the base of the tumor goes beyond the visible edge of the plaque. This study focuses on the shape of 85-Gy isodose lines and on treatment margins for different eye plaque types and tumor sizes and shall help exchange knowledge for ocular brachytherapy.

Entities:  

Keywords:  Brachytherapy; Dosimetry; Eye plaque; Ruthenium; Treatment margin; Treatment planning; Uveal melanoma

Year:  2017        PMID: 30320093      PMCID: PMC6167660          DOI: 10.1159/000479558

Source DB:  PubMed          Journal:  Ocul Oncol Pathol        ISSN: 2296-4657


  18 in total

1.  The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18.

Authors:  M Diener-West; J D Earle; S L Fine; B S Hawkins; C S Moy; S M Reynolds; A P Schachat; B R Straatsma
Journal:  Arch Ophthalmol       Date:  2001-07

2.  Development of a high precision dosimetry system for the measurement of surface dose rate distribution for eye applicators.

Authors:  Marion Eichmann; Dirk Flühs; Bernhard Spaan
Journal:  Med Phys       Date:  2009-10       Impact factor: 4.071

3.  Monte Carlo simulation of ruthenium eye plaques with GEANT4: influence of multiple scattering algorithms, the spectrum and the geometry on depth dose profiles.

Authors:  H Sommer; M Ebenau; B Spaan; M Eichmann
Journal:  Phys Med Biol       Date:  2017-01-04       Impact factor: 3.609

4.  Development of a high-precision xyz-measuring table for the determination of the 3D dose rate distributions of brachytherapy sources.

Authors:  M Eichmann; T Krause; D Flühs; B Spaan
Journal:  Phys Med Biol       Date:  2012-10-19       Impact factor: 3.609

5.  Delivered dose uncertainty analysis at the tumor apex for ocular brachytherapy.

Authors:  Hali Morrison; Geetha Menon; Matthew P Larocque; Hans-Sonke Jans; Ezekiel Weis; Ron S Sloboda
Journal:  Med Phys       Date:  2016-08       Impact factor: 4.071

6.  Monte Carlo Estimation of Absorbed Dose Distributions Obtained from Heterogeneous 106Ru Eye Plaques.

Authors:  Francisco J Zaragoza; Marion Eichmann; Dirk Flühs; Wolfgang Sauerwein; Lorenzo Brualla
Journal:  Ocul Oncol Pathol       Date:  2017-02-23

7.  Accurate estimation of dose distributions inside an eye irradiated with 106Ru plaques.

Authors:  L Brualla; J Sempau; F J Zaragoza; A Wittig; W Sauerwein
Journal:  Strahlenther Onkol       Date:  2012-11-18       Impact factor: 3.621

8.  Monte Carlo Simulation of the Treatment of Eye Tumors with (106)Ru Plaques: A Study on Maximum Tumor Height and Eccentric Placement.

Authors:  Lorenzo Brualla; Francisco J Zaragoza; Wolfgang Sauerwein
Journal:  Ocul Oncol Pathol       Date:  2014-05-07

9.  Intraoperative echographic localization of iodine 125 episcleral radioactive plaques for posterior uveal melanoma.

Authors:  J W Harbour; T G Murray; S F Byrne; J R Hughes; E K Gendron; F J Ehlies; A M Markoe
Journal:  Retina       Date:  1996       Impact factor: 4.256

10.  Comparison of clinical, echographic, and histopathological measurements from eyes with medium-sized choroidal melanoma in the collaborative ocular melanoma study: COMS report no. 21.

Authors: 
Journal:  Arch Ophthalmol       Date:  2003-08
View more
  5 in total

1.  Outcomes following Notched Ruthenium-106 Plaque Brachytherapy for Juxtapapillary Choroidal Melanomas.

Authors:  Manvi Manu Sobti; Magdalena Edington; Julie Connolly; David J McLernon; Stefano Schipani; Diana Ritchie; Paul Cauchi; Vikas Chadha
Journal:  Ocul Oncol Pathol       Date:  2021-08-23

2.  Ruthenium-106 plaque radiotherapy for uveal melanoma: analysis of tumor dimension and location on anatomical and functional results.

Authors:  Reza Mirshahi; Ahad Sedaghat; Ramin Jaberi; Zohreh Azma; Mehdi Mazloumi; Masood Naseripour
Journal:  BMC Ophthalmol       Date:  2022-07-16       Impact factor: 2.086

3.  Monte Carlo Simulation of the Treatment of Uveal Melanoma Using Measured Heterogeneous 106Ru Plaques.

Authors:  Francisco J Zaragoza; Marion Eichmann; Dirk Flühs; Andrea Wittig; Wolfgang Sauerwein; Lorenzo Brualla
Journal:  Ocul Oncol Pathol       Date:  2018-10-15

4.  Evaluation of Hungarian monitoring results and source localization of the 106Ru release in the fall of 2017.

Authors:  Dorottya Jakab; Tünde Ádámné Sió; Gáborné Endrődi; Zsolt Homoki; Sándor Kapitány; András Kocsonya; Júlia Kövendiné Kónyi; András Lencsés; László Manga; Annamária Pántya; Tamás Pázmándi; Krisztián Radó; Péter Rell; Péter Turza; Péter Zagyvai
Journal:  Environ Monit Assess       Date:  2019-06-12       Impact factor: 2.513

5.  Predicting Visual Acuity Deterioration and Radiation-Induced Toxicities after Brachytherapy for Choroidal Melanomas.

Authors:  Charlotte A Espensen; Ane L Appelt; Lotte S Fog; Anita B Gothelf; Juliette Thariat; Jens F Kiilgaard
Journal:  Cancers (Basel)       Date:  2019-08-06       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.